Back to search

France· FR:61861579

ONCASPAR 750 U/ml, poudre pour solution injectable/pour perfusion

A pegaspargase product containing pégaspargase, registered in France by LES LABORATOIRES SERVIER. The same ATC class is registered in 15 of our 19 countries.

ATC L01XX24

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedONCASPAR 750 U/ml, poudre pour soluti…ATCL01XX24REGISTER NO.FR:61861579PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Pegaspargase is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XX24 (pegaspargase), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Pegaspargase · ATC L01XX24

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
PÉGASPARGASE
Manufacturer
LES LABORATOIRES SERVIER
Country
France (FR)
ATC code
L01XX24
ATC class
Pegaspargase
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955046547
    1 flacon en verre de 3750 U

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

441 interactions on record for pegaspargase.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pegaspargase · interactions on record

441 records

  • 30 severe
  • 411 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/59ac577d-ddd9-415c-84e9-7893046cc600
GET /v1/drugs/59ac577d-ddd9-415c-84e9-7893046cc600?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61861579",
  "date_amm": "2017-12-08",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/15/1070",
  "substance": "PÉGASPARGASE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution injectable ou pour perfusion",
  "voies_administration": "intramusculaire;intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about pegaspargase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.